Perspectives

Pharmaphorum: Global upswing in medical writing, with a bout of M&A

The pharma industry has witnessed tremendous growth in the last decade with COVID-19 further fuelling the development of potential treatments, diagnostics, and vaccines at an unprecedented pace. There are now over 5000 companies involved in pharma R&D globally, approximately double that in 2012. The global pharma R&D spending increased from ~$130 billion in 2012 to ~$240 billion in 2022, leading to a doubling of the pipeline drug count. This swift pharma R&D growth has in turn accelerated the growth of…

Continue Reading

Digital Health Innovation: key stakeholders empowering the ecosystem

Technology is becoming an integral part of our lives, making its way into every industry from pharma to aviation. Thus, it is no surprise that it has also gained a strong foothold in driving decisions for better health. The application of digital health is widespread with well-being and fitness apps found on all our phones, from calorie tracker and meditation apps to guided exercises and medication adherence reminders. The umbrella of digital health has 2 specialized sections: Digital Medicine and…

Continue Reading

Biopharma Trend: 7 Tips for Growing a Successful ‘AI in Pharma’ Business: Key Growth Strategy Lessons

The ‘AI in Pharma’ start-up space has been rapidly exploding, with new companies being formed every month. The explosion has been fueled by slow yet steady adoption of such tools by the biopharma companies. However, it’s only a handful number of start-ups that are garnering all the attention while others are struggling to even get a single ‘paid’ project. Several start-ups are likely to die within 2 years, even when they had built great products/ services. A good idea or…

Continue Reading

Biopharma Trend Article: Tech Providers or Biotechs: The Quest to Find an Optimal Business Model Continues for AI Drug Discovery Companies…

The AI drug discovery industry has already gathered momentum with AI start-ups having signed more than 200 deals with 50+ pharma companies over the last few years, and these are just the disclosed deals. Few top companies like InSilico Medicine and Cyclica claim to have over 100 collaborations each with Academia and Industries. With billions of dollars pouring-in, it is likely to gain further impetus with the industry approaching maturity in the next few years from its formative stage. A conundrum that…

Continue Reading

Biopharma Insight Article: The AI Productivity Game in Pharma

The pharmaceutical business is one of the riskiest industries to venture into. Drug discovery is an artisanal process where a carefully designed drug takes about 10 years and approximately 2.5 billion dollars to be approved and launched into the market. The complexity of biological systems places the odds at a ridiculous failure rate of 90%. In recent years, the declining efficiency of the R&D efforts has put the pharma industry on its toes.  In the past decade, Artificial Intelligence (AI)…

Continue Reading

BioSpectrum Article – Time for Asian pharma to up their AI game!

The excitement around Artificial Intelligence’s (AI) potential to transform the drug discovery process has been building up in the biopharma industry. AI-drug discovery starts-ups have boomed in the last decade and billions of dollars have already been poured on the promise of an efficient and agile drug discovery process. AI has influenced all sectors of the drug discovery value chain. Technologies have come up to analyze numerous medical images, to aggregate information from millions of publications for rapid analytics, to…

Continue Reading

BioSpectrum Article – Face-lifting biopharma industry image

Covid-19 pandemic gives an opportunity for the BioPharma industry to transform its image. Can the initiatives and learnings from Covid-19 be applied to other critical therapy areas?  Can the time and cost of development be significantly reduced such that the pharma companies can launch the products at affordable prices to ensure that every patient gets access to the medicines? Emerging markets are gaining more importance than ever, led by China, considering the scales of volumes they offer. With time and…

Continue Reading

5 pitfalls AI healthcare start-ups need to avoid

Artificial intelligence (AI) has now moved beyond its initial hype towards becoming a key part of the pharma industry – with many companies looking to partner with AI drug discovery start-ups. Pharma and healthcare are data-rich industries and AI helps by turning data into actionable insights, allowing us to solve complex, intricate problems. Using machine learning, AI algorithms can generate patterns that will enable us to predict toxicity, find potential combination treatments, identify and predict new drugs and expand usage…

Continue Reading

Mehta Analysis: The Promise Of 2021

Executive Summary Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Between January and early April 2020, over 80 COVID-19-focused programs entered the clinic, seven of which are vaccines. Such advances would normally take 5-10 times longer. Here we focus on two exciting and complementary opportunities. The first is the chance to help society gain a realistic understanding of how an R&D-anchored drug reaches their…

Continue Reading

How AI is fighting COVID-19: the companies using intelligent tech to find new drugs

The use of artificial intelligence (AI) in drug development has been hyped up for some time now – and the COVID-19 pandemic is finally a chance for these technologies to prove their worth. We highlight the companies that are using AI to develop treatments that could end the outbreak. Pharma is facing a race against time to tackle the exponential rise of COVID-19 cases, and as a result there has been an unprecedented level of data sharing and cooperation in…

Continue Reading
Close Menu